MATTHEW KOZICKI: Open Payments
NPI 1124330410 · BLAKESLEE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,459 in 210 payments from 29 companies in 2025. Trend: 2023 $3,076 · 2024 $2,846 · 2025 $3,459
Food & beverage: $3,459
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $440 |
| Novo Nordisk Inc | 21 | $334 |
| PFIZER INC. | 25 | $309 |
| AstraZeneca Pharmaceuticals LP | 8 | $261 |
| Amgen Inc. | 17 | $239 |
| Otsuka America Pharmaceutical, Inc. | 12 | $221 |
| Lilly USA, LLC | 13 | $200 |
| Aimmune Therapeutics, Inc. | 15 | $195 |
| Lundbeck LLC | 11 | $186 |
| GlaxoSmithKline, LLC. | 11 | $159 |
Products named: REXULTI, AIRSUPRA, ZENPEP, QULIPTA, XIFAXAN, Wegovy, OTEZLA, JARDIANCE.
Industry payments across PA — which companies pay providers there.
